Pulmonary Hypertension (PH) Biorepository for Translational Research

Part of paid clinical trials in Baltimore, Maryland.

Sponsor
National Institutes of Health Clinical Center (CC)
Study ID
NCT07647549
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Pulmonary Hypertension

Eligibility Criteria

Sex
ALL
Age
18 Years - 100 Years
Healthy Volunteers
Not accepted

Study Details

Study Description: This study aims to establish a biorepository based on the World Symposium Pulmonary Hypertension (PH) Groups 1-5. In the future, IRB approved protocols may use these blood samples to discover novel, biologically relevant, non-invasive PH biomarkers. In combination with clinical data these potential biomarkers will be used to distinguish PH groups, elucidate underlying molecular phenotypes, predict clinically relevant outcomes, as well as discriminate healthy (healthy subjects will not be enrolled under this protocol) from PH disease states, and differentiate patients with PH from patients without PH. To this end, multimodal genomic, metabolomic, and proteomic assays will eventually be developed and used. Objectives: Primary: Develop a multi-center biorepository of patients suspected of or diagnosed with PH Group 1-5. Secondary: Collect the specific data attributes that may be used in the future to determine whether multimodal genomic, metabolomic or proteomic biomarkers, in combination with clinical data, can: -Elucidate molecular phenotypes that distinguish between patients across PH groups Predict clinically relevant outcomes (i.e., disease severity, disease progression, response to therapy, transplant free survival).

Key Dates

Start date
Aug 3, 2026
Status verified
Jun 2026
Primary completion
Jun 1, 2036
Completion
Jun 1, 2036

Study Design

Enrollment
1,000 participants (estimated)

Arms

  • Arm: Group 1 (suspected of or diagnosed)
    Pulmonary Arterial Hypertension, PAH
  • Arm: Group 2 (suspected of or diagnosed)
    PH due to left heart disease
  • Arm: Group 3 (suspected of or diagnosed)
    PH due to lung diseases and/or hypoxia
  • Arm: Group 4 (suspected of or diagnosed)
    PH due to thromboembolic disease
  • Arm: Group 5 (suspected of or diagnosed)
    PH with unclear or multifactorial mechanisms

Primary Outcome Measure

Develop a multi-center biorepository. [ Time Frame: 10 years ]

Central Contacts

Locations (3)

FacilityCityStateZIPSite coordinators
University of Maryland Medical Center (UMMC) at BaltimoreBaltimoreMaryland21201-
National Institutes of Health Clinical CenterBethesdaMaryland20892
NIH Clinical Center Office of Patient Recruitment (OPR)
[email protected]
800-411-1222
INOVA Fairfax HospitalFalls ChurchVirginia22042-

Find similar trials in Baltimore, MD

By research site
University of Maryland Medical Center (UMMC) at Baltimore· Baltimore, MDNational Institutes of Health Clinical Center· Bethesda, MDINOVA Fairfax Hospital· Falls Church, VA

Related Studies